Artal Group S.A. Buys GDS Holdings, Schrodinger Inc, Black Diamond Therapeutics Inc, Sells Moderna Inc, Avantor Inc, PayPal Holdings Inc

• New Purchases: GDS, SDGR, BDTX, RPRX, NG, AAL, RPTX, MRSN, TECH, IMAB, IMMU, BRKR, HOOK, PASG, ADCT, HTHT, NKTR, TCRR, NTLA, ORIC, AXLA, RNA, ZNTL, YI, KLDO, MGTA, IDYA, EVLO, MEIP, CYRX, PTGX, TORC, VXRT, BLU, CTMX, CDTX,
• Added Positions: BGNE, TBIO, TGTX, BPMC, GOSS, ADVM, AGLE, LPTX, KRYS, REPL, TCOM, TPTX, KURA, AUPH, PRVL, AKBA, BBIO, AGEN, PRTA, STOK,
• Reduced Positions: MRNA, AVTR, PYPL, ALNY, Z, FOLD, BNTX, XLRN, IOVA, QURE, FGEN, FATE, EPZM, DCPH, VNET, BABA, ASND, HARP, SAGE, ARGX, PRNB, YMAB, STNE, MORF, TCDA, ALBO, MRUS, SWTX, SELB, ALEC, NERV, AGIO, DNLI, AUTL, RGNX, ADPT, ARAV, APTX, SPRO, IMUX, ORTX, PRQR, ADRO, TRIL, AXDX, CRIS, CYCN, RIGL, ACIU, SYRS,
• Sold Out: ARWR, UBER, CLVS, BLUE, PTLA,

For the details of Artal Group S.A.'s stock buys and sells, go to https://www.gurufocus.com/guru/artal+group+s.a./current-portfolio/portfolio

1. WW International Inc (WW) - 14,818,300 shares, 10.70% of the total portfolio.
2. JPMorgan Chase & Co (JPM) - 3,000,000 shares, 8.03% of the total portfolio.
3. BeiGene Ltd (BGNE) - 850,000 shares, 4.56% of the total portfolio. Shares added by 30.77%
4. BioNTech SE (BNTX) - 2,000,000 shares, 3.80% of the total portfolio. Shares reduced by 10.24%
5. Alnylam Pharmaceuticals Inc (ALNY) - 900,000 shares, 3.79% of the total portfolio. Shares reduced by 18.18%

Artal Group S.A. initiated holding in GDS Holdings Ltd. The purchase prices were between $50.62 and $81.92, with an estimated average price of $61.56. The stock is now traded at around $80.05. The impact to a portfolio due to this purchase was 2.49%. The holding were 1,100,000 shares as of .

Artal Group S.A. initiated holding in Schrodinger Inc. The purchase prices were between $36.12 and $91.57, with an estimated average price of $57.89. The stock is now traded at around $68.63. The impact to a portfolio due to this purchase was 2.34%. The holding were 897,445 shares as of .

Artal Group S.A. initiated holding in Black Diamond Therapeutics Inc. The purchase prices were between $22.3 and $44.8, with an estimated average price of $36.52. The stock is now traded at around $30.58. The impact to a portfolio due to this purchase was 1.85%. The holding were 1,546,517 shares as of .

Artal Group S.A. initiated holding in Royalty Pharma PLC. The purchase prices were between $44.5 and $52.11, with an estimated average price of $49.5. The stock is now traded at around $44.62. The impact to a portfolio due to this purchase was 1.04%. The holding were 750,000 shares as of .

Artal Group S.A. initiated holding in Novagold Resources Inc. The purchase prices were between $7.38 and $12.14, with an estimated average price of $10.1. The stock is now traded at around $9.44. The impact to a portfolio due to this purchase was 0.68%. The holding were 2,600,000 shares as of .

Artal Group S.A. initiated holding in American Airlines Group Inc. The purchase prices were between $9.04 and $20.31, with an estimated average price of $12.1. The stock is now traded at around $12.60. The impact to a portfolio due to this purchase was 0.56%. The holding were 1,500,000 shares as of .

Artal Group S.A. added to a holding in BeiGene Ltd by 30.77%. The purchase prices were between $123.11 and $195.41, with an estimated average price of $161.93. The stock is now traded at around $231.96. The impact to a portfolio due to this purchase was 1.07%. The holding were 850,000 shares as of .

Artal Group S.A. added to a holding in Translate Bio Inc by 166.67%. The purchase prices were between $8.33 and $26.66, with an estimated average price of $15.01. The stock is now traded at around $15.84. The impact to a portfolio due to this purchase was 0.51%. The holding were 1,600,000 shares as of .

Artal Group S.A. added to a holding in TG Therapeutics Inc by 75.00%. The purchase prices were between $8.9 and $21.84, with an estimated average price of $16.01. The stock is now traded at around $22.67. The impact to a portfolio due to this purchase was 0.42%. The holding were 1,750,000 shares as of .

Artal Group S.A. added to a holding in Blueprint Medicines Corp by 37.50%. The purchase prices were between $57.09 and $79.27, with an estimated average price of $67.44. The stock is now traded at around $75.00. The impact to a portfolio due to this purchase was 0.33%. The holding were 550,000 shares as of .

Artal Group S.A. added to a holding in Gossamer Bio Inc by 46.99%. The purchase prices were between $9.52 and $15.98, with an estimated average price of $12.52. The stock is now traded at around $14.00. The impact to a portfolio due to this purchase was 0.31%. The holding were 2,658,968 shares as of .

Artal Group S.A. added to a holding in Aeglea BioTherapeutics Inc by 175.00%. The purchase prices were between $4.01 and $11.04, with an estimated average price of $7.56. The stock is now traded at around $6.85. The impact to a portfolio due to this purchase was 0.18%. The holding were 1,100,000 shares as of .

Artal Group S.A. sold out a holding in Arrowhead Pharmaceuticals Inc. The sale prices were between $26.12 and $43.27, with an estimated average price of $35.18.

Artal Group S.A. sold out a holding in Uber Technologies Inc. The sale prices were between $22.82 and $37.21, with an estimated average price of $31.11.

Artal Group S.A. sold out a holding in Clovis Oncology Inc. The sale prices were between $5.69 and $9.69, with an estimated average price of $7.53.

Artal Group S.A. sold out a holding in bluebird bio Inc. The sale prices were between $41.88 and $70.98, with an estimated average price of $57.98.

Artal Group S.A. sold out a holding in Portola Pharmaceuticals Inc. The sale prices were between $6.41 and $17.99, with an estimated average price of $13.76.